Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

489 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y. Chang CH, et al. Among authors: nelson js. Cancer. 1983 Sep 15;52(6):997-1007. doi: 10.1002/1097-0142(19830915)52:6<997::aid-cncr2820520612>3.0.co;2-2. Cancer. 1983. PMID: 6349785 Clinical Trial.
Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02.
Curran WJ Jr, Scott CB, Weinstein AS, Martin LA, Nelson JS, Phillips TL, Murray K, Fischbach AJ, Yakar D, Schwade JG, et al. Curran WJ Jr, et al. Among authors: nelson js. J Clin Oncol. 1993 May;11(5):857-62. doi: 10.1200/JCO.1993.11.5.857. J Clin Oncol. 1993. PMID: 8487050 Clinical Trial.
Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Werner-Wasik M, Scott CB, Nelson DF, Gaspar LE, Murray KJ, Fischbach JA, Nelson JS, Weinstein AS, Curran WJ Jr. Werner-Wasik M, et al. Among authors: nelson js, nelson df. Cancer. 1996 Apr 15;77(8):1535-43. doi: 10.1002/(SICI)1097-0142(19960415)77:8<1535::AID-CNCR17>3.0.CO;2-0. Cancer. 1996. PMID: 8608540 Clinical Trial.
A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02.
Curran WJ Jr, Scott CB, Nelson JS, Weinstein AS, Phillips TL, Murray K, Fischbach AJ, Yakar D, Schwade JG, Powlis WD, et al. Curran WJ Jr, et al. Among authors: nelson js. Cancer. 1992 Dec 15;70(12):2909-17. doi: 10.1002/1097-0142(19921215)70:12<2909::aid-cncr2820701230>3.0.co;2-6. Cancer. 1992. PMID: 1451073 Clinical Trial.
Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
Prados MD, Scott CB, Rotman M, Rubin P, Murray K, Sause W, Asbell S, Comis R, Curran W, Nelson J, Davis RL, Levin VA, Lamborn K, Phillips TL. Prados MD, et al. Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):653-9. doi: 10.1016/s0360-3016(97)00770-0. Int J Radiat Oncol Biol Phys. 1998. PMID: 9486616
Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
Nelson DF, Curran WJ Jr, Scott C, Nelson JS, Weinstein AS, Ahmad K, Constine LS, Murray K, Powlis WD, Mohiuddin M, et al. Nelson DF, et al. Among authors: nelson js. Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):193-207. doi: 10.1016/0360-3016(93)90340-2. Int J Radiat Oncol Biol Phys. 1993. PMID: 8380567 Clinical Trial.
489 results